FDA reviewer Nancy Xu says Cornerstone's (CRTX +5.3%) Lixivaptan drug should be approved to treat low sodium levels in the blood due to a condition that causes the body to have excess water. However, Xu says Lixivaptan shouldn't be authorized for heart-failure patients. An FDA advisory panel is due to meet on Thursday.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs
Next headline on your portfolio: